These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 14593182)

  • 1. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
    Changelian PS; Flanagan ME; Ball DJ; Kent CR; Magnuson KS; Martin WH; Rizzuti BJ; Sawyer PS; Perry BD; Brissette WH; McCurdy SP; Kudlacz EM; Conklyn MJ; Elliott EA; Koslov ER; Fisher MB; Strelevitz TJ; Yoon K; Whipple DA; Sun J; Munchhof MJ; Doty JL; Casavant JM; Blumenkopf TA; Hines M; Brown MF; Lillie BM; Subramanyam C; Shang-Poa C; Milici AJ; Beckius GE; Moyer JD; Su C; Woodworth TG; Gaweco AS; Beals CR; Littman BH; Fisher DA; Smith JF; Zagouras P; Magna HA; Saltarelli MJ; Johnson KS; Nelms LF; Des Etages SG; Hayes LS; Kawabata TT; Finco-Kent D; Baker DL; Larson M; Si MS; Paniagua R; Higgins J; Holm B; Reitz B; Zhou YJ; Morris RE; O'Shea JJ; Borie DC
    Science; 2003 Oct; 302(5646):875-8. PubMed ID: 14593182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
    Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
    Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.
    Conklyn M; Andresen C; Changelian P; Kudlacz E
    J Leukoc Biol; 2004 Dec; 76(6):1248-55. PubMed ID: 15371489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
    Borie DC; O'Shea JJ; Changelian PS
    Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin.
    Stepkowski SM; Erwin-Cohen RA; Behbod F; Wang ME; Qu X; Tejpal N; Nagy ZS; Kahan BD; Kirken RA
    Blood; 2002 Jan; 99(2):680-9. PubMed ID: 11781254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts.
    Paniagua R; Si MS; Flores MG; Rousvoal G; Zhang S; Aalami O; Campbell A; Changelian PS; Reitz BA; Borie DC
    Transplantation; 2005 Nov; 80(9):1283-92. PubMed ID: 16314797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection.
    Stepkowski SM; Nagy ZS; Wang ME; Behbod F; Erwin-Cohen R; Kahan BD; Kirken RA
    Transplant Proc; 2001; 33(7-8):3272-3. PubMed ID: 11750401
    [No Abstract]   [Full Text] [Related]  

  • 8. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
    Deuse T; Hua X; Taylor V; Stubbendorff M; Baluom M; Chen Y; Park G; Velden J; Streichert T; Reichenspurner H; Robbins RC; Schrepfer S
    Transplantation; 2012 Oct; 94(7):695-702. PubMed ID: 22971540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib in kidney transplantation.
    Wojciechowski D; Vincenti F
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.
    Deuse T; Velotta JB; Hoyt G; Govaert JA; Taylor V; Masuda E; Herlaar E; Park G; Carroll D; Pelletier MP; Robbins RC; Schrepfer S
    Transplantation; 2008 Mar; 85(6):885-92. PubMed ID: 18360272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates.
    Borie DC; Larson MJ; Flores MG; Campbell A; Rousvoal G; Zhang S; Higgins JP; Ball DJ; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Changelian PS
    Transplantation; 2005 Dec; 80(12):1756-64. PubMed ID: 16378072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The specificity of JAK3 kinase inhibitors.
    Changelian PS; Moshinsky D; Kuhn CF; Flanagan ME; Munchhof MJ; Harris TM; Whipple DA; Doty JL; Sun J; Kent CR; Magnuson KS; Perregaux DG; Sawyer PS; Kudlacz EM
    Blood; 2008 Feb; 111(4):2155-7. PubMed ID: 18094329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting JAK3 in kidney transplantation: current status and future options.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2011 Dec; 16(6):614-9. PubMed ID: 21971513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection.
    Wang M; Kirken R; Behbod F; Erwin-Cohen R; Stepkowski SM; Kahan BD
    Transplant Proc; 2001; 33(1-2):201. PubMed ID: 11266779
    [No Abstract]   [Full Text] [Related]  

  • 15. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
    West K
    Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
    Rovira J; Ramírez-Bajo MJ; Banon-Maneus E; Lazo-Rodríguez M; Moya-Rull D; Hierro-Garcia N; Tubita V; Piñeiro GJ; Revuelta I; Ventura-Aguiar P; Cucchiari D; Oppenheimer F; Brunet M; Campistol JM; Diekmann F
    Transplantation; 2018 Jul; 102(7):1075-1084. PubMed ID: 29620612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase 3: a novel target for selective transplant immunosupression.
    Podder H; Kahan BD
    Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts.
    Kirken RA; Erwin-Cohen R; Behbod F; Wang M; Stepkowski SM; Kahan BD
    Transplant Proc; 2001; 33(1-2):95. PubMed ID: 11266723
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
    Flanagan ME; Blumenkopf TA; Brissette WH; Brown MF; Casavant JM; Shang-Poa C; Doty JL; Elliott EA; Fisher MB; Hines M; Kent C; Kudlacz EM; Lillie BM; Magnuson KS; McCurdy SP; Munchhof MJ; Perry BD; Sawyer PS; Strelevitz TJ; Subramanyam C; Sun J; Whipple DA; Changelian PS
    J Med Chem; 2010 Dec; 53(24):8468-84. PubMed ID: 21105711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice.
    Wang Y; Qin Q; Chen J; Kuang X; Xia J; Xie B; Wang F; Liang H; Qi Z
    Transpl Immunol; 2009 Dec; 22(1-2):5-11. PubMed ID: 19766187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.